Related Experiment Video
Updated: Nov 16, 2025
Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
Published on: February 23, 2024
Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy
Tomohiro Hayashi1, Takamasa Nukui1, Jin-Lan Piao1
1Department of Neurology, Faculty of Medicine, University of Toyama, Toyama, Japan.
Objectives:
Neurofilament light chain (NfL) levels have been suggested as reflecting axonal damage in various inflammatory and neurodegenerative disorders, including acquired peripheral neuropathies. We aimed to investigate if serum NfL (sNfL) levels can be a biomarker of disease activity and treatment response in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Materials And Methods:
The sNfL levels of eleven newly diagnosed patients with CIDP were retrospectively assayed and compared with seven healthy volunteers. The levels were assayed before and after intravenous immunoglobulin treatment in patients with CIDP and were also assayed in the remission period.
Results:
Baseline sNfL levels in patients with CIDP before treatment were significantly higher than those in healthy controls. The levels significantly decreased overtime after one month of treatment and in remission period. There were significant negative correlations between the sNfL levels and the disease duration (the interval between the onset of the disease and the time of sampling), and weak correlations between the sNfL levels and overall neuropathy limitations scale.
Conclusions:
sNfL may be a potential biomarker reflecting the disease activity in patients with CIDP.
